Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NGM Biopharmaceuticals
Biotech
VC firm that took NGM private oversees biotech’s $122M series A
Three months after The Column Group acquired NGM to take the biotech private, the VC firm has overseen a series A to fund trials of two lead assets
James Waldron
Jul 17, 2024 7:42am
NGM to go private as part of $135M buyout by VC firm Column
Feb 26, 2024 10:26am
NGM hunts for light at end of tunnel with NASH trial
May 5, 2023 1:13pm
Amarin CEO abruptly resigns—Chutes & Ladders
Apr 7, 2023 9:30am
NGM Bio CEO reveals what led to 33% head count reduction
Apr 5, 2023 9:55am
Merck bails on NGM eye disease collab in wake of trial failure
Dec 21, 2022 9:09am
